The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients

Table 4

The effects of thiazolidinediones on glycemic indeces in controlled trials with HIV infected, HAART-treated patients. HAART = highly active antiretroviral therapy, HOMA = homeostasis model assessment (fasting insulin [𝜇IU/ml] × fasting glucose [mmol/L]/22.5), OGTT = oral glucose tolerance test, NS = nonsignificant, NR = not reported, AUC = area under the curve.

𝑁	Drug	Duration	Insulin (𝜇IU/ml)	HOMA	OGTT	Fasting glucose (mmol/L)	Reference
30	Rosi versus placebo	24 weeks	Rosi: −3.3, ^∗𝑃<.05; pla: +6.7, ^∗NSΔ rosi versus pla 𝑃<.05	NR	NR	NS	Sutinen et al. [55]
108	Rosi versus placebo	48 weeks	Rosi: −3.5; pla: +0.7 Δ rosi versus pla 𝑃=.02	Rosi: −1.0; pla: +0.04 Δ rosi versus pla 𝑃=.03	2 h glucose: NS 2 h insulin: rosi −13.6; pla +3.9 Δ rosi versus pla 𝑃=.09	NS	Carr et al. [56]
14	Pio versus feno versus pio + feno versus placebo	12 months	NS	Pio: −3.8, ^∗𝑃<.05; pla: −1.3, ^∗NS	NR	NS	Gavrila et al. [65]
96	Rosi versus placebo	24 weeks	NS	NS	NS	NS	Cavalcanti et al. [62]
28	Rosi versus placebo	3 months	NS	NR	2 h glucose: rosi: −0.3; pla: +0.1 Δ rosi versus pla 𝑃=.06 2h insulin AUC: rosi: −2.3; pla: +1.8 Δ rosi versus pla 𝑃=.003	NS	Hadigan et al. [57]
105	Rosi versus metformin versus rosi + met versus placebo	16 weeks	Rosi: −4, ^∗𝑃=.08; met: −2, ^∗𝑃=.07	NR	Insulin AUC: rosi: −26, ^∗𝑃=.012; met: −11, ^∗𝑃=.06; rosi + met: −18, ^∗𝑃=.002Δ rosi + met versus placebo 𝑃=.03; Δ rosi versus pla 𝑃=.07	NS	Mulligan et al. [60]
130	Pio versus placebo	48 weeks	NS	NS	NS	NS	Slama et al. [66]
37	Rosi versus placebo	6 months	NS	Rosi: −0.1, ^∗NS; pla: +1.3, ^∗𝑃<.05 At 6 months: rosi versus pla 𝑃<.05	NR	NS	Haider et al. [61]
90	Rosi versus metformin versus No-treatment	48 weeks	Rosi: −19.3, ^∗𝑃<.001; met: −11.1, ^∗𝑃<.001; No-Tx: +0.7, ^∗NS At 48 weeks: rosi versus No-Tx 𝑃<.001; met versus No-Tx 𝑃<.001; met versus rosi 𝑃<.001	Rosi: −7.3, ^∗𝑃<.001; met: −6.2, ^∗𝑃<.001; No-Tx: +0.3, ^∗NS At 48 weeks: rosi versus No-Tx 𝑃<.001; met versus No-Tx 𝑃<.001; rosi versus met 𝑃<.001	NR	Rosi: −1.9, ^∗𝑃<.001; met: −2.2, ^∗𝑃<.001; No-Tx: 0.0, ^∗NS At 48 weeks: Rosi versus No-Tx 𝑃<.001; met versus No-Tx 𝑃<.001; rosi versus met 𝑃=.015	Silič et al. [63]
39	Rosi versus metformin	26	NR	NR	Glucose AUC: rosi: −1.9, ^∗𝑃=.04; met: −1.1, ^∗𝑃=.05Δ rosi versus met NS Insulin AUC: rosi: −37, ^∗𝑃=.01; met −33, ^∗𝑃=.01 Δ rosi versus met NS	NR	van Wijk et al. [58]

∗denotes significance within the study group compared to baseline value, Δ denotes comparison of the change between respective study groups.